Unsolicited Checkpoint Pharmacology

The cooler bag is legal. The 90-second monologue on triple agonist receptor selectivity is what makes him reconsider his career.

Filed under Survodutide ·Tirzepatide ·Pramlintide · #stack-life ·#glp-1 ·#cope

Active Compounds

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Tirzepatide · Dual GIP/GLP-1 Receptor Agonist

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

Pramlintide · Amylin Analogue

An FDA-approved synthetic analogue of amylin used alongside insulin for diabetes, also studied for weight management.

RX: Survodutide · Tirzepatide · Pramlintide
Dosage: one unprompted monologue
Half-life: until boarding group 3
Source: manual
Tags: stack-life , glp-1 , cope
Stamped: 2026-08-25 · Cycle 034
Lot #: LOT-20260825T15:20:23.850Z